On June 2, 2014, Biocept Inc (NASDAQ:BIOC) announced the launch of its estrogen receptor (ER) status testing on CTCs that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory. Biocept Inc (NASDAQ:BIOC) weekly performance is -16.91%. On last trading day company shares ended up $4.62. Biocept Inc (NASDAQ:BIOC) distance from 50-day simple moving average (SMA50) is -12.84%.
On May 13, Egalet Corp (NASDAQ:EGLT) reported business highlights and financial results for the three months ended March 31, 2014. Cash as of March 31, 2014 was $77.5 million compared to $15.7 million at December 31, 2013. Revenues increased to $256,000 for the three months ended March 31, 2014 from zero for the three months ended March 31, 2013, as a result of the amortization of deferred revenue and the performance of certain research and development services under our collaborative agreement with Shionogi Limited. Egalet Corp (NASDAQ:EGLT) shares closed at 13.63% in last trading session. EGLT return on assets is -191.80%. Egalet Corp (NASDAQ:EGLT)quarterly performance is -26.76%.
Jefferies says it is “increasingly excited” about the potential for Mirati Therapeutics, Inc. (NASDAQ:MRTX) be the next “breakthrough cancer story” based on ‘265 in mutation-specific lung and head and neck cancer patients. It has a Buy rating on the stock with a $34 price target. Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares closed at 20.88 in last trading session, while 52 week range of $5.25 – $25.97. Mirati Therapeutics, Inc. (NASDAQ:MRTX) year to date (YTD) performance is 25.56%.
Hyperion Therapeutics Inc (NASDAQ:HPTX) saw a big move on Friday, as the company’s shares fell about 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for HPTX as the stock is now up nearly 9% in the past one-month time frame. Hyperion Therapeutics Inc (NASDAQ:HPTX) ended the last trading day at $26.00. Company weekly volatility is calculated as 7.96% and price to cash ratio as 6.62. Hyperion Therapeutics Inc (NASDAQ:HPTX) showed a negative weekly performance of -9.75%.
Shares of Synergetics USA Inc (NASDAQ:SURG) are down on Tuesday after it reported lower results for its third quarter ended April 30. The medical device maker posted net income of 4 cents per diluted share, compared to 5 cents per diluted share in the same period a year ago. Synergetics USA Inc (NASDAQ:SURG) net profit margin is 5.10% and weekly performance is -2.48%. On last trading day company shares ended up $3.15. Analysts mean target price for the company is $6.00. Synergetics USA Inc (NASDAQ:SURG)distance from 50-day simple moving average (SMA50) is -5.75%.